Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Pro-Pharmaceuticals, Inc.
Pro-Pharmaceuticals’ Chief Scientist Published Articles in Three Prestigious Peer-Reviewed Journals
July 7th, 2009
Pro-Pharmaceuticals, Inc. (OTC: PRWP), a developer of carbohydrate-based targeted therapeutic compounds to treat cancer and fibrosis, announced that its Chief Scientist and co-founder, Anatole Klyosov, Ph.D., published articles in: the Biochemical Journal, Carbohydrate Research and Glycobiology that further define the mechanism of action of its lead compound DAVANAT® and the role it plays in the treatment of cancer. "The nuclear magnetic resonance (NMR) studies demonstrate a strong interaction between DAVANAT® and the Galectin receptors found on the surface of solid tumors," said Dr. Klyosov. "Understanding the interaction between carbohydrate drugs such as DAVANAT® and...
Source: Cancer Weekly (2009-07-07)
|
